Tutti gli studi
AutorizzatoEsplorativo terapeutico (Fase II)Interventistico

HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)

Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are slow-growing blood cancers. Although existing treatments can keep the condition under control for a long time, the cancer often returns or stops responding to medication. This trial, called the ODYSSEUS study, is testing whether combining two newer cancer medicines works better than current options. One drug, pirtobrutinib, is taken as a daily tablet that blocks signals cancer cells need to survive. The second drug, epcoritamab, is an injection that helps your own immune system find and destroy cancer cells. Researchers want to find out how safe this combination is and whether it can keep the cancer under control for at least two years. Participants receive close medical care, including regular health checks, scans, and blood tests, to track how well the treatment is working.

A colpo d'occhio

Stato
Autorizzato
Fase
Esplorativo terapeutico (Fase II)
Sponsor
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Obiettivo di iscrizione
58
Inizio
20 Jul 2026

Di cosa tratta questo studio?

Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are related forms of blood cancer that affect white blood cells called lymphocytes. For many people, initial treatments work well to manage the condition. However, it is very common for the cancer to come back (relapse) or to stop responding to standard medicines over time (refractory disease). When this happens, patients and their doctors need new, effective options.

This study, called ODYSSEUS (HOVON 180 CLL), is testing a modern approach that brings together two different targeted therapies: pirtobrutinib and epcoritamab. Pirtobrutinib is a daily tablet that works by turning off a specific protein that leukaemia cells need to grow. Epcoritamab is a specialised antibody given by injection. It acts like a bridge, latching onto both cancer cells and your body's immune cells at the same time to help your immune system attack the leukaemia.

Doctors want to learn two main things from this study. First, they need to confirm that taking both drugs together is safe and manageable. Second, they want to see if this combination can keep the cancer from growing for two years or more, and whether it can clear away even tiny traces of cancer cells that standard tests might miss.

By taking part, participants help doctors understand whether combining targeted tablets with immune-boosting injections can provide a longer-lasting remission for people whose leukaemia has proven difficult to treat.

Punti chiave

  • Tests a new two-drug combination for adults with relapsed or hard-to-treat CLL or SLL.
  • Combines daily pirtobrutinib tablets with epcoritamab injections under the skin.
  • Aims to control the cancer for two years while monitoring safety and quality of life.
  • Requires regular hospital visits for check-ups, blood tests, and scans.
  • Participation is entirely voluntary, and you can withdraw at any time.

Chi può essere idoneo?

This study is open to adults aged 18 and over who have been diagnosed with either chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). To be considered, your cancer must have returned after previous therapy or stopped responding to the treatments you have already tried.

You will need to be well enough in your daily life to attend regular hospital appointments, swallow tablets, and undergo routine health checks.

You might not be able to take part if you have certain other active, serious health problems—such as severe infections or major heart disease—or if you are pregnant or breastfeeding. Your hospital doctor will look closely at your past treatments and general health to see if this study is suitable for you.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. I am aged 18 or older.
  2. I have a confirmed diagnosis of CLL or SLL.
  3. My cancer has come back or stopped responding after past treatment.
  4. I am able to attend regular hospital appointments and take daily tablets.
  5. I do not have an active, uncontrolled severe infection.
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

Taking part in this study lasts for up to two years of active treatment, followed by ongoing check-ups. You will take pirtobrutinib as a tablet by mouth once a day for up to 24 cycles (about two years). You will also receive epcoritamab as an injection under the skin for 12 cycles (about one year).

At the start of the study, you will need to visit the hospital more frequently for treatment and safety checks. Over time, these visits will become less frequent. During your visits, the research team will take blood tests, perform physical examinations, and check for any side effects. You will also have periodic scans and bone marrow tests to see how the cancer is responding, and you will be asked to fill in brief questionnaires about your daily wellbeing and quality of life.

Rischi e benefici potenziali

The possible benefit of joining this trial is that the study drugs may help shrink or control your leukaemia when other treatments have stopped working. You will also receive very close, regular monitoring by a specialist team. However, there is no guarantee the treatment will work for you. Like all cancer medicines, both drugs can cause side effects, which may include fatigue, low blood counts, increased risk of infection, or immune-related reactions. Your medical team will watch you closely and treat any side effects promptly. Joining is entirely your choice, and you are free to leave the trial at any time without it affecting your regular NHS care.

Luoghi (1)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Paesi Bassi

Domande comuni

Qual è l'obiettivo principale di questo studio?

The study aims to see if combining pirtobrutinib tablets with epcoritamab injections is safe and effective at keeping relapsed CLL or SLL under control for two years or longer.

How are the medicines given?

Pirtobrutinib is taken as tablets swallowed once a day at home. Epcoritamab is given as an injection under the skin during your hospital visits.

Will I have to pay for the trial treatment?

No. In the UK, trial medications and tests related to the study are provided free of charge, and your standard care remains covered by the NHS.

What happens if I experience unpleasant side effects?

The research team will check on you regularly. If you have side effects, doctors can give you medications to help, adjust your study drug doses, or pause treatment if necessary.

Can I leave the trial if I change my mind?

Yes. Taking part is completely voluntary. You can stop participating at any point, and your doctor will discuss standard alternative treatment options with you.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.